IP Library Granted Patent US 9,193,960
Granted Patent B2
US 9,193,960 · App. 13/732,831 · Granted Nov 24, 2015

High fidelity restriction endonucleases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,193,960
App. No.
13/732,831
Granted
Nov 24, 2015
Kind
B2
Abstract

Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.

Claims (8)

1. A composition comprising a variant PstI restriction endonuclease having reduced star activity, wherein the variant PstI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent PstI restriction endonuclease by an amino acid substitution at position corresponding to position 204, in SEQ ID NO:91.

2. The composition according to claim 1 , wherein the amino acid substitution is E204G.

3. A composition comprising a variant PstI restriction endonuclease having reduced star activity, wherein the variant PstI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent PstI restriction endonuclease by an amino acid substitution at a position corresponding to position 91 in SEQ ID NO 91.

4. The composition according to claim 3 , wherein the amino acid substitution is D91A.

5. A composition comprising a variant PstI restriction endonuclease having reduced star activity, wherein the variant PstI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent PstI restriction endonuclease by a substitution at an amino acid position corresponding to position 228 in SEQ ID NO:91.

6. The composition according to claim 5 , wherein the substitution is K228A.

7. A composition comprising a variant PstI restriction endonuclease having reduced star activity, wherein the variant PstI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent PstI restriction endonuclease by amino acid substitutions at positions corresponding to positions 228 and 289 in SEQ ID NO:91.

8. The composition according to claim 7 , wherein the substitutions are K228A and A289V.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2015
From: ZHU, ZHENYU; BLANCHARD, AINE; XU, SHUANG-YONG; GUAN, SHENGXI; WEI, HUA; ZHANG, PENGHUA; SUN, DAPENG; CHAN, SIU-HONG
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 035067/0775 →